Flag of the European Union EU Clinical Trials Register Help

Clinical trials for multiple sclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    631 result(s) found for: multiple sclerosis. Displaying page 32 of 32.
    «« First « Previous 24  25  26  27  28  29  30  31  32 
    EudraCT Number: 2005-001338-33 Sponsor Protocol Number: TOPMAT-PEP-3001 Start Date*: 2006-01-20
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concur...
    Medical condition: Partial Onset Epilepsy and other Seizures
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FI (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) NO (Ongoing) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001836-44 Sponsor Protocol Number: UCL/11/0119 Start Date*: 2012-06-11
    Sponsor Name:University College London
    Full Title: A Phase II Trial to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients with Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
    Medical condition: Patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000679-16 Sponsor Protocol Number: EORTC 06023 Start Date*: 2005-05-17
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized phase II trial with infliximab (Remicade) in patients with myelodysplastic syndrome and a relatively low risk of developing acute leukemia
    Medical condition: myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10028533 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-001512-28 Sponsor Protocol Number: COVIM Start Date*: 2021-05-11
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Immunogenicity of COVID-19 vaccines in medical staff and special risk populations
    Medical condition: SARS-CoV-2 immunogenicity
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000785-18 Sponsor Protocol Number: HIPRA-HH-4 Start Date*: 2022-05-09
    Sponsor Name:HIPRA SCIENTIFIC
    Full Title: A Phase III, open label, single arm, multi-center, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1...
    Medical condition: SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005329-11 Sponsor Protocol Number: FX006-2014-008 Start Date*: 2015-02-26
    Sponsor Name:Flexion Therapeutics
    Full Title: A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients with Osteoarthritis of the Knee
    Medical condition: Osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) LT (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003752-21 Sponsor Protocol Number: BN40898(SA-307JG) Start Date*: 2014-05-19
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with neuromyelitis...
    Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) PL (Completed) HU (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-009216-53 Sponsor Protocol Number: 191622-094 Start Date*: 2009-04-04
    Sponsor Name:Allergan Ltd
    Full Title: A Multicenter, Long-term Follow-up Study of the Safety and Efficacy of Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Urinary Incontinence Due to Ne...
    Medical condition: Urinary incontinence due to neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029279 Neurogenic bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) NL (Completed) GB (Completed) FR (Completed) DE (Completed) IT (Completed) ES (Completed) BE (Completed) AT (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000748-16 Sponsor Protocol Number: MT-2-01 Start Date*: 2017-09-14
    Sponsor Name:Minoryx Therapeutics S.L.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTICENTER STUDY WITH OPEN-LABEL TREATMENT EXTENSION TO ASSESS THE EFFECT OF MIN-102 ON THE PROGRESSION OF ADRENOMYELONEUROPATHY IN M...
    Medical condition: ADRENOMYELONEUROPATHY IN MALE PATIENTS WITH X-LINKED ADRENOLEUKODYSTROPHY
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) ES (Ongoing) NL (Completed) PL (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000422-38 Sponsor Protocol Number: PET_imaging_of_Tau Start Date*: 2014-09-19
    Sponsor Name:Skåne University Hospital, Region Skåne
    Full Title: An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau
    Medical condition: Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnost...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    17.0 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    17.0 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    17.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    17.0 10029205 - Nervous system disorders 10012285 Dementia due to Pick's disease LLT
    17.0 10029205 - Nervous system disorders 10012267 Dementia PT
    17.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    17.0 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004784-58 Sponsor Protocol Number: MRI-0143 Start Date*: 2007-06-22
    Sponsor Name:University of Leuven
    Full Title: Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn’s disease
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 24  25  26  27  28  29  30  31  32 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 15 13:40:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA